Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication

Journal of Virology

Volumn 70, Issue 9, 1996, Pages 5840-5844

  Kaplan, Andrew H ^a   Manchester, Marianne ^b,d   Smith, Terri ^b   Yang, Yan Li ^a   Swanstrom, Ronald ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE;

ARTICLE; DNA SYNTHESIS; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0029793658     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.9.5840-5844.1996     Document Type: Article

References (41)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Ashorn, P., T. J. McQuade, S. Thaisrivongs, A. G. Tomasselli, W. G. Tarpley, and B. Moss. 1990. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc. Natl. Acad. Sci. USA 87:7472-7476.
3. Baboonian, C., A. Dalgleish, L. Bountiff, J. Gross, S. Oroszlan, G. Rickett, B. C. Smith, P. Troke, and J. Merson. 1991. HIV-1 proteinase is required for synthesis of proviral DNA. Biochem. Biophys. Res. Commun. 179:17-24.
4. Bennett, R. P., S. Rhee, H. C. Craven, E. Hunter, and J. W. Wills. 1991. Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J. Virol. 65:272-280.
5. Crawford, S., and S. P. Goff. 1985. A deletion mutation in the 5′ part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J. Virol. 53:899-907.
6. Darke, P. L., S. P. Jordan, D. L. Hall, J. A. Zugay, J. A. Shafer, and L. C. Kuo. 1994. Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates. Biochemistry 33:98-105.
7. Erickson, J., D. J. Neidhart, J. VanDrie, D. J. Kempf, X. C. Wang, D. W. Norbeck, J. J. Plattner, J. W. Rittenhouse, M. Turon, N. Wideburg, W. E. Kohlbrenner, R. Simmer, R. Helfrich, D. A. Paul, and M. Knigge. 1990. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249:527-533.
8. Gottlinger, H. G., J. G. Sodroski, and W. A. Haseltine. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86:5781-5785.
9. Hsu, H. W., P. Schwartzberg, and S. P. Goff. 1985. Point mutations in the P30 domain of the gag gene of Moloney murine leukemia virus. Virology 142:211-214.
10. Jacobsen, H., L. L. Ahlborn, R. Gugel, and J. Mous. 1992. Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease. J. Virol. 66:5087-5091.
11. Kaplan, A., M. Manchester, and R. Swanstrom. 1994. Analysis of the role of the HIV-1 protease in virion assembly. Methods Enzymol. 241:58-69.
12. Kaplan, A. H., S. F. Michael, R. S. Wehble, M. F. Knigge, D. A. Paul, L. Everitt, D. J. Kempf, D. W. Norbeck, J. W. Erickson, and R. Swanstrom. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91:5597-5601.
13. Katoh, I., Y. Yosbinaka, A. Rein, M. Shibuya, T. Odaka, and S. Oroszlan. 1985. Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity. Virology 145:280-292.
14. Kempf, D. J., K. C. Marsh, D. A. Paul, M. F. Knigge, D. W. Norbeck, W. E. Kohlbrenner, L. Codacovi, S. Vasavanonda, P. Bryant, X. C. Wang, N. E. Wideburg, J. J. Clement, J. J. Plattner, and J. Erickson. 1991. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 35:2209-2214.
15. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Viral. 66:2232-2239.
16. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
17. Lee, P. P., and M. L. Linial. 1994. Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal. J. Virol. 68:6644-6654.
18. Lillehoj, E. P., F. H. Salazar, R. J. Mervis, M. G. Raum, H. W. Chan, N. Ahmad, and S. Venkatesan. 1988. Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus. J. Virol. 62:3053-3058.
19. Manchester, M. Unpublished observation.
20. Manchester, M., L. Everitt, D. D. Loeb, C. A. Hutchison III, and R. Swanstrom. 1994. Identification of temperature-sensitive mutants of the human immunodeficiency virus type 1 protease through saturation mutagenesis. J. Biol. Chem. 269:7689-7695.
21. Meek, T. D., D. M. Lambert, G. B. Dreyer, T. J. Carr, T. J. Tomaszek, M. L. Moore, J. E. Strickler, C. Debouck, L. J. Hyland, T. J. Matthews, B. W. Metcalf, and S. R. Petteway. 1990. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (London) 343:90-92.
22. Mitsuya, H., K. J. Welnhold, P. A. Furman, C. M. St, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type HI/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100.
23. Nagy, K., M. Young, C. Baboonian, J. Merson, P. Whittle, and S. Oroszlan. 1994. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase. J. Virol. 68:757-765.
24. Oroszlan, S., and R. B. Luftig. 1990. Retroviral proteinases. Curr. Top. Microbiol. Immunol. 157:153-185.
25. Pargellis, C. A., M. M. Morelock, E. T. Graham, P. Kinkade, S. Pav, K. Lubbe, D. Lamarre, and P. C. Anderson. 1994. Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer. Biochemistry 33:12527-12534.
26. Peng, C., B. K. Ho, T. W. Chang, and N. T. Chang. 1989. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63:2550-2256.
27. Pettit, S. C., M. D. Moody, R. S. Wehbie, A. H. Kaplan, P. V. Nantermet, C. A. Klein, and R. Swanstrom. 1994. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68:8017-8027.
28. Ratner, L., A. Fisher, L. L. Jagodzinski, H. Mitsuya, R. S. Liou, R. C. Gallo, and S. F. Wong. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses 3:57-69.
29. Reicin, A. S., S. Paik, R. D. Berkowitz, J. Luban, I. Lowy, and S. P. Golf. 1995. Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J. Virol. 69:642-650.
30. Roberts, M. M., T. D. Copeland, and S. Oroszlan. 1991. In situ processing of a retroviral nucleocapsid protein by the viral proteinase. Protein Eng. 4:695-700.
31. Roberts, M. M., and S. Oroszlan. 1989. The preparation and biochemical characterization of intact capsids of equine infectious anemia virus. Biochem. Biophys. Res. Commun. 160:486-494.
32. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krohn, R. W. Lambert, J. H. Merrett, J. S. Mills, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. C. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
33. Sambrook, J., T. Maniatis, and E. F. Fritsch. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
34. Sommerfelt, M. A., S. S. Rhee, and E. Hunter. 1992. Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity. J. Virol. 66:7005-7011.
35. Stewart, L., G. Schatz, and V. M. Vogt 1990. Properties of avian retrovirus particles defective in viral protease. J. Virol. 64:5076-5092.
36. Strambio de Castillia, C., and E. Hunter. 1992. Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J. Virol. 66:7021-7032.
37. Venaud, S., N. Yahi, J. L. Fehrentz, N. Guettari, D. Nisato, I. Hirsch, and J. C. Chermann. 1992. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication. Res. Virol. 143:311-319.
38. von der Helm, K. 1977. Cleavage of Rous sarcoma viral polypeptide precursor into internal structural proteins in vitro involves viral protein p15. Proc. Natl. Acad. Sci. USA 74:911-915.
39. Wang, C. T., and E. Barklis. 1993. Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J. Virol. 67:4264-4273.
40. Yoshinaka, Y., and R. B. Luftig. 1977. Properties of a P70 proteolytic factor of murine leukemia viruses. Cell 12:709-719.
41. Yu, X., Q. C. Yu, T. H. Lee, and M. Essex. 1992. The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J. Virol. 66:5667-5670.